Cambridge, Mass., October 19, 2023 – In a pioneering move, Flagship Pioneering announces the fusion of Laronde and Senda Biosciences, birthing Sail Biomedicines—a trailblazing force in the evolution of fully programmable medicines poised to redefine patient care. Dr. Guillaume Pfefer, Ph.D., and MBA, the current CEO-Partner at Flagship Pioneering, will spearhead Sail as its CEO and board member, with Dr. John Mendlein, Executive Partner at Flagship Pioneering, assuming the role of Executive Chairman.
Sail Biomedicines leverages over eight years of collaborative data and platform development from Laronde and Senda Biosciences. Senda’s platform, utilizing a universal chemical code within natural nanoparticles, allows precise deployment of payloads, like translatable RNA, to designated cells.
Simultaneously, Laronde’s groundbreaking Endless RNA (eRNA), a synthetic RNA class, presents substantial therapeutic potential.
Dr. Mendlein underscores the potential of Endless RNA to inaugurate a new era of programmable medicines, deliverable to cells and tissues through unique deployment molecules. He envisions leveraging proprietary generative AI technologies and rapid prototyping as pivotal for achieving breakthroughs beyond current human comprehension.
Dr. Pfefer highlights Sail’s deployment platform, utilizing natural nanoparticles to transport biomolecules into human cells with unique tropism, potency, and redosability. His vision is to expedite the development of new product candidates, form strategic partnerships, and unlock diverse value pools for the swift delivery of transformative vaccines and therapies.
Noubar Afeyan, Ph.D., Founder and CEO of Flagship Pioneering, expresses confidence in Sail Biomedicines, stating, “I am confident the combined leadership team and board will carry forward this company to realize its bold ambitions and ultimately deliver maximum impact for patients.”
The Sail Biomedicines Board of Directors, including Drs. Mendlein and Pfeffer, comprises individuals from the Laronde and Senda Biosciences boards, alongside experts from Incyte, ADC Therapeutics, Massachusetts Institute of Technology, and Flagship Pioneering.
About Sail Biomedicines
Sail Biomedicines pioneers the integrative design and deployment of fully programmable medicines, combining programmable circular RNA technology (Endless RNA™ or eRNA) with an industry-leading platform of programmable nanoparticles.
About Flagship Pioneering
Flagship Pioneering is a biotechnology company inventing and building platform companies, each harboring the potential for transformative products in human health or sustainability. Since 2000, Flagship has shepherded over 100 ventures, resulting in over $90 billion in aggregate value, with a current ecosystem comprising 43 companies.
Check out our mRNA service to expedite your vaccine research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
[2024/11/15] Gene and Cell Therapy- weekly digest from PackGene
FeaturedNewsArticlesPackGene's NewsletterReceive the latest news and insights to your inbox.About PackGenePackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span...
One-time gene therapy reverses liver disease MASH in mouse models
Credit: Molecular Therapy (2024). DOI: 10.1016/j.ymthe.2024.10.023UAB researchers have reversed metabolic dysfunction-associated steatohepatitis (MASH) in mouse models. MASH is a severe liver disease associated with obesity and type 2 diabetes that affects more than...
PTC Therapeutics Achieves FDA Approval for First Brain-Administered Gene Therapy
Breakthrough Approval for Kebilidi The FDA has granted a landmark approval to PTC Therapeutics' Kebilidi, making it the first gene therapy in the U.S. to be administered directly into the brain. This approval represents a major step forward in gene therapy, offering...
FDA Approves Autolus’ New CAR-T Therapy for Aggressive Blood Cancer
In a significant development for cancer treatment, the US Food and Drug Administration (FDA) has approved Autolus Therapeutics’ CAR-T cell therapy for adult patients with relapsed or treatment-resistant B cell precursor acute lymphoblastic leukemia (B-ALL). This...
Related Services
Plasmids GMP Services
AAV GMP Services
